Trial · NCT03441555
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT03441555, Phase 1, Completed, AbbVie
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia. Trials, record NCT03441555. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03441555
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- NCT number
- NCT03441555
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 36 participants, actual
- Lead sponsor
- AbbVie
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Venetoclax, Alvocidib
- First posted
- 2018-02-22
- Last updated
- 2022-02-01
- Other registries' IDs
- eudract:2017-002531-42
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tmax of venetoclax | Approximately 32 days after first dose of study drug | Time to maximum plasma concentration (Tmax) of venetoclax |
| Primary | Clearance of Alvocidib | Approximately 32 days after first dose of study drug | Clearance (CL) of alvocidib |
| Primary | AUC0-∞ of Alvocidib | Approximately 32 days after first dose of study drug | Area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) post-dose of alvocidib |
| Primary | Cmax of Venetoclax | Approximately 32 days after first dose of study drug | Maximum plasma concentration (Cmax) of venetoclax |
| Primary | Half-life (t1/2) of Alvocidib | Approximately 32 days after first dose of study drug | Half-life (t1/2) of alvocidib |
| Primary | AUC0-24 Post-dose of Venetoclax | Approximately 32 days after first dose of study drug | Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax. |
| Primary | Cmax of Alvocidib | Approximately 32 days after first dose of study drug | Maximum plasma concentration (Cmax) of alvocidib. |
| Primary | AUCt Post-dose of Alvocidib | Approximately 32 days after first dose of study drug | Area under the plasma concentration-time curve from time zero to time t (AUCt) post-dose alvocidib. |
| Primary | Dose Escalation Phase: Recommended Phase 2 dose (RPTD) for Venetoclax and Alvocidib | Minimum first cycle of dosing (up to 28 days) | RPTD will be determined using available safety and pharmacokinetics data upon completion of the dose escalation phase. |
| Secondary | Complete Response (CR) Rate | Up to approximately 8 months | CR is defined as the proportion of participants with documented complete response (CR) based on International Working Group (IWG) criteria. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03441555
GET https://conductscience.org/api/trials/v1/NCT03441555/registered